Breast Cancer

Only half of those with breast cancer and one-quarter of those with colon cancer were referred for genetic counseling or testing by their physicians.

Dr. Hope Rugo, from the UCSK Comprehensive Cancer Center, on the First-line Superiority of Paclitaxel for Advanced Breast Cancer.

Dr. Kimberly Blackwell, from the Duke Cancer Institute, Discusses the T-DM1 EMILIA Trial

T-DM1 extended progression-free survival by 3.2 months in women with HER2-positive locally advanced or metastatic breast cancer.

CDX-011, a targeted therapy designed to treat patients with advanced breast cancer, appears to increase PFS in TNBC patients who have received multiple prior lines of therapy and express GPNMB.

Detecting hereditary cancer and providing genetic counseling can help prevent a new primary cancer and may also help to protect family members from developing cancer.

Breast cancer survivors who are younger, closer to the time of surgery, or have upper-extremity lymphedema may be less likely to undergo repeat mammography.

At this year's annual NCCN conference, the organization presented updates in 13 areas, including specific disease states and general screening methods.

Celldex Therapeutics will present the interim results of a phase IIb study testing the efficacy of a new monoclonal antibody in patients with advanced breast cancer.

Roughly one-third of women with early-stage breast cancer develop intolerable adverse effects during aromatase inhibitor therapy.

Dr. Neil Spector, from Duke Cancer Institute, Explains Breast Cancer Heterogeneity

Three prominent breast cancer clinicians and researchers share their opinions on adjuvant anthracyclines, fluoropyrimidines, and taxane agents for women with early breast cancer.

In a six-week span, José Baselga, MD, PhD, notched a stunning series of milestones in breast cancer research that could potentially change practice in different subtypes of the disease.

Dr. Matthew Ellis, from Siteman Cancer Center, on Heterogeneity Impacting Biomarker Efficacy

J. Michael Dixon, MBChB, MD, and Patrick I. Borgen, MD, discuss the pros and cons of long-term clinical follow-up care of patients with breast cancer.

Standards for identifying appropriate populations for treatment with HER2-targeted therapies are evolving.

Understanding the genetic basis of breast and ovarian cancers is essential to providing patients with effective preventive and/or management strategies that can improve outcomes.

Dr. J. Michael Dixon, from Western General Hospital, Scotland, Advises Against Mastectomies

A discussion with Pat Whitworth, Jr, MD, on how breast cancer treatment has evolved from a 'kitchen sink' approach with chemotherapy to a new paradigm that targets chemosensitivity.

Debu Tripathy, MD, from the University of Southern California Norris Comprehensive Cancer Center, was one of four co-chairs of the 2012 Miami Breast Cancer Conference.

Researchers have determined that breast cancer can be classified into 10 different subtypes instead of four subtypes as previously thought.

Dr. Edith Perez, from the Mayo Clinic, Describes the Breast Cancer Translational Genomics Program

Monitoring bone health and ensuring adequate calcium and vitamin D intake in postmenopausal women who are taking exemestane for the primary prevention of breast cancer is essential.

Dr. Maxine Jochelson, from Memorial Sloan-Kettering Cancer Center, Discusses Complementary Breast Cancer Screening Techniques

First-line treatment patterns for metastatic triple-negative breast cancer are diverse, reflecting a lack of consensus and an unmet need for standardized therapy.